Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs Nuwellis Inc — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $43.42 (market cap $746.48M), while Nuwellis Inc trades at $0.7 (market cap $2.20M). The key difference: Rex Fang & Innovation Equity Premium Income ETF is far larger — about 339.3× Nuwellis Inc's market cap, and Rex Fang & Innovation Equity Premium Income ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rex Fang & Innovation Equity Premium Income ETF for 56 Days and Nuwellis Inc for 26 Days on average.
| FEPI | NUWE | |
|---|---|---|
Market Cap | $746.48M | $2.20M |
Volume | 334,337 | 121,544 |
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $146.65 |
52-Week Low | $37.98 | $0.68 |
Typical Hold Time | 56 Days | 26 Days |
Enterprise Value | — | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $43.59, down 0.17% on the day, with a bullish technical signal supported by moving averages. The ETF employs a covered call strategy on AI and tech mega-caps, generating weekly dividends averaging $0.20-0.21 per share. Recent news highlights its high yield but notes underperformance versus peers in total return.
Outlook: High income potential via dividends but capped upside from call-writing. Risks include concentrated tech exposure, volatility sensitivity, and competitive pressure from alternative yield strategies. Neutral sentiment prevails amid yield appeal and growth constraints.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
